Benefits
Studied in people with seasonal hay fever
In one randomized, double-blind, placebo-controlled trial published in 2004, adults with seasonal allergic rhinoconjunctivitis took a Perilla frutescens extract enriched for rosmarinic acid at 50 mg or 200 mg a day for 21 days. More people on the extract responded for itchy nose, watery eyes and itchy eyes than on placebo, and nasal wash samples showed fewer inflammatory cells. This was a single small trial of a plant extract rather than pure rosmarinic acid, it enrolled people who already had seasonal allergy, and it has not been independently replicated.
Cognitive and memory effects are not established
No study cited on this page measured memory, attention or any other thinking skill, so there is no support here for rosmarinic acid protecting the brain or slowing cognitive decline. The research often quoted on this topic used lemon balm extracts, not isolated rosmarinic acid, and was done in people diagnosed with a medical condition, which says nothing about memory in healthy people.
Anti-inflammatory activity seen in laboratory studies
In cell and animal experiments, rosmarinic acid quiets NF-kB, a master switch that turns on inflammatory genes such as TNF-alpha, IL-6 and COX-2. This is laboratory work only. The one human trial cited here measured hay fever symptoms and inflammatory cells in nasal wash fluid, not body-wide inflammation, so it is unknown whether this mechanism matters at supplement doses in people.
Calming and mood effects have not been tested here
Lemon balm is a traditional calming herb and rosmarinic acid is one of the compounds it contains, but no study cited on this page tested mood, anxiety or sleep. The palpitations study sometimes quoted for this used a whole lemon balm extract in people with an existing heart symptom, and it does not show that rosmarinic acid was the reason for any change.
Mechanism of action
NF-κB pathway suppression (the core anti-inflammatory mechanism)
In laboratory studies, rosmarinic acid blocks the breakdown of a protein called IκBα, which keeps the inflammatory signal NF-κB p65 out of the cell nucleus. This downregulates transcription of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and adhesion molecules. In animal models of allergy it also shifts the balance of immune signalling. This is a proposed explanation for the hay fever findings, not a proven one, because the mechanism was never measured in the human trial.
Free radical scavenging in the test tube
Its chemical structure carries two pairs of neighbouring hydroxyl groups, which let it neutralize free radicals in a test tube. Test tube antioxidant scores such as ORAC do not predict what happens inside the body, and no study cited on this page measured any antioxidant marker in people.
Amyloid-beta clumping in cell and animal models
In test tube and animal experiments, rosmarinic acid interferes with the clumping of a protein called amyloid-beta. This is early laboratory work only. It has not been shown to happen in people taking a supplement, and it is not evidence that rosmarinic acid prevents or treats Alzheimer's disease.
GABA enzyme effects in preclinical studies
Laboratory work suggests rosmarinic acid can slow the enzyme that breaks down GABA, a calming brain chemical. This is a proposed mechanism from preclinical studies only. No human study cited here measured anxiety or sleep, and comparing a plant compound to a prescription medicine is not appropriate.
Clinical trials
Randomized, double-blind, placebo-controlled clinical trial (Takano H, Osakabe N, Sanbongi C, Yanagisawa R, Inoue K, Yasuda A, Natsume M, Baba S, Ichiishi E, Exp Biol Med 229(3):247-254, doi:10.1177/153537020422900305).
Patients with seasonal allergic rhinoconjunctivitis (SAR) randomized to 50 mg or 200 mg/day rosmarinic-acid-enriched Perilla frutescens extract or placebo for 21 days. Symptoms recorded daily; nasal lavage performed periodically.
Dose-dependent significant increase in responder rates for itchy nose, watery eyes, itchy eyes, and total symptoms (P<0.05 vs placebo). Active treatment significantly decreased neutrophils and eosinophils in nasal lavage fluid (P<0.05 vs placebo). No adverse events reported; routine blood tests normal. The authors concluded the extract may help mild seasonal allergic rhinoconjunctivitis by reducing white blood cell infiltration in the nose. Limitations: a single small trial published in 2004, testing a Perilla frutescens extract enriched for rosmarinic acid rather than the pure compound, in people already diagnosed with seasonal allergy, over only 21 days, and not independently replicated.
Clinical and mechanistic trial (Osakabe N, Takano H, Sanbongi C, Yasuda A, Yanagisawa R, Inoue K, Biofactors 21(1-4):127-131).
SAR patients treated daily with rosmarinic acid (200 mg or 50 mg) or placebo for 21 days. Daily symptom recording; nasal lavage profiles of infiltrating cells and cytokines measured.
This short report describes symptom changes and fewer inflammatory cells in nasal wash fluid in people with seasonal allergy, alongside a separate animal experiment in which rosmarinic acid was applied to the skin. It comes from the same research group as the 2004 trial and overlaps with it rather than independently confirming it, and it is not among this page's verified references. Applying a compound to animal skin says nothing about what a capsule does in a person.
Randomized, double-blind, placebo-controlled trial (Noguchi-Shinohara M, Hamaguchi T, Sakai K, Komatsu J, Iwasa K, Horimoto M, Nakamura H, Yamada M, Ono K 2023, J Alzheimers Dis 91(2):805-814, doi:10.3233/JAD-220953).
323 older adults with subjective or mild cognitive impairment. Randomized to Melissa officinalis extract containing 500 mg/day rosmarinic acid vs placebo for 96 weeks (followed by 24-week washout).
The main outcome, the ADAS-Cog cognition score, did not show a significant benefit over placebo; only trends were reported, which means the trial did not demonstrate an effect. The extract was well tolerated over 96 weeks. It tested a Melissa officinalis (lemon balm) extract rather than isolated rosmarinic acid, in older adults with subjective or mild cognitive impairment, and it is not among this page's verified references. A trial with a null primary result is not evidence that rosmarinic acid prevents Alzheimer's disease.